ACADIA PHARMACEUTICALS INC 8-K

What Happened
On January 13, 2026 Acadia Pharmaceuticals, Inc. filed an 8-K (Item 2.02/Item 7.01) reporting that, in a presentation at the J.P. Morgan Healthcare Conference, the company said it anticipates 2025 net sales will exceed $1 billion — a statement the company described as consistent with its prior guidance. Acadia posted the related corporate slide presentation on its investor website (ir.acadia.com).

Key Details

• Presentation and filing date: January 13, 2026 (J.P. Morgan Healthcare Conference).
• 2025 outlook: company expects 2025 net sales to exceed $1 billion.
• Guidance status: outlook described as consistent with prior guidance (no change announced).
• Disclosure posted: corporate slide presentation uploaded to Acadia’s investor website.

Why It Matters
The company’s confirmation that 2025 net sales should exceed $1 billion is a material revenue outlook point for investors and analysts — it signals continued revenue growth expectations and reaffirms prior guidance. The filing does not provide additional line-item financials or changes to guidance beyond that statement, so investors should look for full quarterly or annual releases for detailed earnings and revenue figures.